Understanding FDA Regulatory Requirements for Investigational New Drug Applications for Sponsor-Investigators

Abstract

Clinical investigators invoke a number of specific regulatory requirements if their study includes use of a pharmaceutical agent. Studies using a drug that has not been approved by the Food and Drug Administration (FDA) or for indications not in the approved labeling may require filing an Investigational New Drug (IND) application with the FDA. If a study meets specific regulatory exemption criteria, then an IND may not be needed. Individual investigators may meet the FDA definition of a sponsor-investigator, in which case the application process is generally less complicated than for commercial sponsors, and this review addresses only this circumstance. Filing an IND requires completion of 3 sets of forms: 1 detailing the study (FDA Form 1571), 1 providing information about the investigator and study site (FDA Form 1572), and 1 certifying that the study is registered in the national database of clinical trials (FDA Form 3674). If the IND is approved, the study may begin 30 days after the FDA acknowledges receipt and assigns an IND. If the FDA requires additional information or if the study is placed on a “clinical hold,” the study must not proceed. While the IND is active, the investigator must also continue to meet a set of regulations for monitoring the study and reporting to the FDA.

Keywords

food and drug administration investigational new drug sponsor-investigator federal regulations investigational drug studies

Get full access to this article

View all access options for this article.

References

Federal Food, Drug, and Cosmetic Act.

CFR Title 21 Part 312. Investigational New Drug Application.

CDER Original INDs Received, Calendar Years 1986-2006. January 29, 2007. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM165257.pdf. Accessed June 16, 2009.

Center for Biologics Evaluation and Research Organization. May 28, 2009. Available at: http://www.fda.gov/AboutFDA/CentersOffices/OrganizationCharts/ucm135943.htm. Accessed June 16, 2009.

Center for Drug Evaluation and Research Organization. May 28, 2009. Available at: http://www.fda.gov/AboutFDA/CentersOffices/OrganizationCharts/ucm135674.htm. Accessed June 16, 2009.

Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Available at: http://www.fda.gov/downloads/AboutFDA/CentersOffices/OrganizationCharts/UCM144011.pdf. Accessed June 16, 2009.

CFR Title 21 Database Search. April 1, 2008. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312. Accessed May 14, 2009.

Guidance for Industry, Investigators, and Reviewers, Exploratory IND Studies. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf. Accessed June 16, 2009.

Code of Federal Regulations Title 21 Part 310. “New Drugs”.

10.

Guidance for Industry. IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071717.pdf. Accessed June 16, 2009.

11.

Investigational New Drug (IND) Guidances. April 30, 2009. Available at: http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/ucm094297.htm. Accessed June 16, 2009.

12.

Division of Antiviral Products-ODE IV Pre-IND Consultation Program. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/Overview/ucm077776.htm. Accessed June 16, 2009.

13.

Investigational New Drug (IND) Application. June 2, 2009. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/default.htm. Accessed June 16, 2009.

14.

Information for Sponsor-Investigators Submitting Investigational New Drug Applications (INDs). April 30, 2009. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm071098.htm. Accessed June 16, 2009.

15.

Investigational New Drug (IND) or Device Exemption (IDE) Process (CBER). June 15, 2009. Available at: http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/default.htm. Accessed June 16, 2009.

16.

US Public Law 110-85 (Food and Drug Administration Amendments Act of 2007), Title VIII, Section 801.

17.

Protocol Registration System Information. Available at: https://register.clinicaltrials.gov/. Accessed May 14, 2009.

18.

Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff. Certifications to Accompany Drug, Biological Product, and Device Applications/Submissions: Compliance With Section 402(j) of the Public Health Service Act, Added By Title VIII of the Food and Drug Administration Amendments Act of 2007. June 8, 2009. Available at: http://www.fda.gov/RegulatoryInformation/Guidances/ucm125335.htm. Accessed June 16, 2009.